In the midst of savoring slices of crispy pizza at Pizzeria da Laura in Berkeley, gene editing expert Fyodor Urnov and venture capitalist Johnny Hu brainstormed a revolutionary idea for a new CRISPR company. This encounter took place in the spring of 2024, with Urnov, a renowned professor at the University of California, Berkeley, and Hu, a former gene editing researcher turned principal at Menlo Ventures, sparking a conversation that would shape the future of genetic therapeutics.
Urnov had been passionately advocating for the utilization of CRISPR technology to treat individuals with rare genetic mutations. He believed that with the right approach from regulators and businesses, CRISPR could potentially help numerous patients with these ultra-rare conditions. Hu, drawing from his background in gene editing, was eager to contribute to this mission.
As they delved deeper into their discussion, Hu posed a crucial question to Urnov – how feasible was their vision? Urnov, confident in the technological capabilities of CRISPR, shifted the focus back to Hu, challenging him to consider the practical aspects of building a successful company around this concept.
The conversation laid the foundation for what would later become Aurora Therapeutics, a startup aimed at harnessing the power of CRISPR to address rare genetic disorders. The synergy between Urnov’s expertise in gene editing and Hu’s business acumen set the stage for a collaboration that could potentially revolutionize the field of genetic medicine.
Their meeting over pizza served as the catalyst for a bold new venture that promised to bring hope to patients with genetic conditions that had long been overlooked. With a shared passion for innovation and a drive to make a tangible impact in the world of healthcare, Urnov and Hu embarked on a journey to turn their vision into reality.
The story of Aurora Therapeutics is a testament to the transformative potential of interdisciplinary collaboration and the boundless possibilities that arise when brilliant minds come together with a shared purpose. As they continue to push the boundaries of what is possible in the realm of genetic therapeutics, Urnov and Hu’s partnership serves as a beacon of hope for those in need of cutting-edge medical solutions.
